![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received for publication December 21, 2005.
Revised January 30, 2006.
Accepted for publication January 30, 2006.
1(I) Collagen Gene Promoter Specific Triplex Forming Oligonucleotides after Conjugation with Cholesterol
A triplex forming oligonucleotide (TFO) specific for type 
1(I) collagen promoter is a promising candidate for treating liver fibrosis. Earlier, we determined the pharmacokinetics and biodistribution of TFO after systemic administration into normal and fibrotic rats. In this study, we conjugated cholesterol to the 3' end of the TFO via a disulfide bond and determined its cellular and nuclear uptake, and bioactivity using HSC-T6 cell lines in vitro, followed by biodistribution at whole body, organ (liver) and subcellular levels. Conjugation with cholesterol had little effect on the triplex forming ability of the TFO with target duplex DNA and the cellular uptake of 33P-TFO-Chol increased by 2~4 folds. Real time RT-PCR analysis after transfection of HSC-T6 cells with TFO-Chol or TFO indicated that TFO-Chol had higher inhibition on type 1(I) collagen primary transcript than naked TFO at low concentration (200nM), but showed similar inhibition at higher concentration (500nM and 1000nM). There was increase in the inhibition on primary transcript with transfection time. The hepatic uptake of 33P-TFO-Chol after systemic administration was 72.22% of the dose compared to 45.8% of 33P-TFO. There was significant increase in the uptake of 33P-TFO-Chol by HSCs and hepatocytes. More importantly, the nuclear uptake of TFO-Chol was higher than TFO in cell culture system and in vivo studies. In conclusion, TFO-Chol is a potential antifibrotic agent.
Key words:
Triplex Forming Oligonucleotide, bioconjugation, cholesterol, liver fibrosis, real time PCR, transcription inhibition
This article has been cited by other articles:
|
|
 |
|
  M. Duca, P. Vekhoff, K. Oussedik, L. Halby, and P. B. Arimondo The triple helix: 50 years later, the outcome Nucleic Acids Res., September 1, 2008; 36(16): 5123 - 5138. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Yuan, L. Lanting, Z.-G. Xu, S.-L. Li, P. Swiderski, S. Putta, M. Jonnalagadda, M. Kato, and R. Natarajan Effects of cholesterol-tagged small interfering RNAs targeting 12/15-lipoxygenase on parameters of diabetic nephropathy in a mouse model of type 1 diabetes Am J Physiol Renal Physiol, August 1, 2008; 295(2): F605 - F617. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Paramasivam, S. Cogoi, V. V. Filichev, N. Bomholt, E. B. Pedersen, and L. E. Xodo Purine twisted-intercalating nucleic acids: a new class of anti-gene molecules resistant to potassium-induced aggregation Nucleic Acids Res., June 1, 2008; 36(10): 3494 - 3507. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. DiFiglia, M. Sena-Esteves, K. Chase, E. Sapp, E. Pfister, M. Sass, J. Yoder, P. Reeves, R. K. Pandey, K. G. Rajeev, et al. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits PNAS, October 23, 2007; 104(43): 17204 - 17209. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. De Paula, M. V. L.B. Bentley, and R. I. Mahato Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting RNA, April 1, 2007; 13(4): 431 - 456. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
